Unnamed Project

The FY15 JPC-8/CRMRP ERI is intended to support Phase I, II, or pivotal clinical trial phase development projects focused on extremity regeneration. The focus is on bone and soft tissue reconstruction, limb and tissue salvage technologies, and regenerative medicine technologies for the treatment of trauma-induced damage. All clinical trials must be responsive to the health care needs of military Service members and Veterans, as well as the general public. All proposals/applications must specifically and clearly address the military relevance of the proposed research.
Proposals/applications submitted to the FY15 JPC-8/CRMRP ERI must specifically address one or more of the Focus Areas listed below.
The treatment of soft tissue injury, specifically, nerve, muscle, and vascular injury to the extremities. The aim of these technologies is to: (a) maintain the structure and function of end organs distal to a nerve injury, (b) restore functional muscle tissue, and (c) restore vascular perfusion. Both innovative care solutions as well as innovative technologies that may better enable a definitive care solution to be delivered at some future time point, such as vascular shunting or stenting technologies, will be considered.
The treatment for bone healing, specifically technologies that create a wound environment more conducive to bone healing following injury to the extremities.
Funding from this award mechanism must support a clinical trial and development-related efforts and may not be used for preclinical research studies. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. The term quote mark human subjects quote mark is used in this BAA to refer to individuals who will be recruited for or who will participate in the proposed clinical trial. For more information, a Human Subject Resource Document is provided at https://cdmrp.org/Program_Announcements_and_Forms/.

Additional Information: Interested/eligible applicants are instructed to visit www.grants.gov to access the full announcement.

Point of Contact: 301-682-5507; help@eBRAP.org (CDMRO help desk)

Proposal/Application Submission Deadline: 22 December 2015

Contracting Office Address: US Army Medical research Acquisition Activity, 820 Chandler Street, Frederick, MD 21702-5014

POC: Abigail Strock; Abigail.l.strock.civ@mail.mil